Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens

Shio Shin Jean, Po Ren Hsueh

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Nosocomial pneumonia (including ventilator-associated pneumonia; VAP), a consistently difficult-to-treat entity, is frequently caused by multidrug-resistant (MDR) or pandrug-resistant (PDR) bacteria. Given the high mortality rates caused by drug-resistant bacteria and the difficulty of developing new potent antibiotics to target the problematic pathogens, combination regimens are under ardent evaluation as new strategies to overcome increasing drug resistance. Adjustment of the administration method of certain β-lactams (meropenem, or imipenem/cilastatin), or combination of tigecycline with some agents, may show promise with regard to successful management of MDR or PDR Acinetobacter baumannii pneumonia. Additionally, vancomycin plus rifampicin is an effective regimen against nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) responding poorly to vancomycin monotherapy. The clinical appropriateness of parenteral colistin against pneumonia caused by MDR A. baumannii has been established in a clinical trial. Facing the decline of clinical vancomycin efficacy after initial use, linezolid might be the drug of choice with regard to the treatment of MRSA-VAP. The role of tigecycline monotherapy for the management of nosocomial pneumonia caused by MRSA and extended-spectrum β-lactamase-producing Enterobacteriaceae needs to be cautiously evaluated.

Original languageEnglish
Pages (from-to)2145-2148
Number of pages4
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number14
DOIs
Publication statusPublished - Oct 2011
Externally publishedYes

Fingerprint

Pneumonia
Vancomycin
Methicillin-Resistant Staphylococcus aureus
Acinetobacter baumannii
Linezolid
meropenem
Bacteria
Colistin
Ventilator-Associated Pneumonia
Lactams
Enterobacteriaceae
Rifampin
Drug Resistance
Pharmaceutical Preparations
Clinical Trials
Anti-Bacterial Agents
Mortality
tigecycline

Keywords

  • Acinetobacter baumannii
  • colistin
  • extended-spectrum β-lactamase
  • methicillin-resistant Staphylococcus aureus
  • multidrug-resistant
  • nosocomial pneumonia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens. / Jean, Shio Shin; Hsueh, Po Ren.

In: Expert Opinion on Pharmacotherapy, Vol. 12, No. 14, 10.2011, p. 2145-2148.

Research output: Contribution to journalArticle

@article{8f439713b36e4c6c9eceb93dfd6dbae3,
title = "Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens",
abstract = "Nosocomial pneumonia (including ventilator-associated pneumonia; VAP), a consistently difficult-to-treat entity, is frequently caused by multidrug-resistant (MDR) or pandrug-resistant (PDR) bacteria. Given the high mortality rates caused by drug-resistant bacteria and the difficulty of developing new potent antibiotics to target the problematic pathogens, combination regimens are under ardent evaluation as new strategies to overcome increasing drug resistance. Adjustment of the administration method of certain β-lactams (meropenem, or imipenem/cilastatin), or combination of tigecycline with some agents, may show promise with regard to successful management of MDR or PDR Acinetobacter baumannii pneumonia. Additionally, vancomycin plus rifampicin is an effective regimen against nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) responding poorly to vancomycin monotherapy. The clinical appropriateness of parenteral colistin against pneumonia caused by MDR A. baumannii has been established in a clinical trial. Facing the decline of clinical vancomycin efficacy after initial use, linezolid might be the drug of choice with regard to the treatment of MRSA-VAP. The role of tigecycline monotherapy for the management of nosocomial pneumonia caused by MRSA and extended-spectrum β-lactamase-producing Enterobacteriaceae needs to be cautiously evaluated.",
keywords = "Acinetobacter baumannii, colistin, extended-spectrum β-lactamase, methicillin-resistant Staphylococcus aureus, multidrug-resistant, nosocomial pneumonia",
author = "Jean, {Shio Shin} and Hsueh, {Po Ren}",
year = "2011",
month = "10",
doi = "10.1517/14656566.2011.599320",
language = "English",
volume = "12",
pages = "2145--2148",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "14",

}

TY - JOUR

T1 - Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens

AU - Jean, Shio Shin

AU - Hsueh, Po Ren

PY - 2011/10

Y1 - 2011/10

N2 - Nosocomial pneumonia (including ventilator-associated pneumonia; VAP), a consistently difficult-to-treat entity, is frequently caused by multidrug-resistant (MDR) or pandrug-resistant (PDR) bacteria. Given the high mortality rates caused by drug-resistant bacteria and the difficulty of developing new potent antibiotics to target the problematic pathogens, combination regimens are under ardent evaluation as new strategies to overcome increasing drug resistance. Adjustment of the administration method of certain β-lactams (meropenem, or imipenem/cilastatin), or combination of tigecycline with some agents, may show promise with regard to successful management of MDR or PDR Acinetobacter baumannii pneumonia. Additionally, vancomycin plus rifampicin is an effective regimen against nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) responding poorly to vancomycin monotherapy. The clinical appropriateness of parenteral colistin against pneumonia caused by MDR A. baumannii has been established in a clinical trial. Facing the decline of clinical vancomycin efficacy after initial use, linezolid might be the drug of choice with regard to the treatment of MRSA-VAP. The role of tigecycline monotherapy for the management of nosocomial pneumonia caused by MRSA and extended-spectrum β-lactamase-producing Enterobacteriaceae needs to be cautiously evaluated.

AB - Nosocomial pneumonia (including ventilator-associated pneumonia; VAP), a consistently difficult-to-treat entity, is frequently caused by multidrug-resistant (MDR) or pandrug-resistant (PDR) bacteria. Given the high mortality rates caused by drug-resistant bacteria and the difficulty of developing new potent antibiotics to target the problematic pathogens, combination regimens are under ardent evaluation as new strategies to overcome increasing drug resistance. Adjustment of the administration method of certain β-lactams (meropenem, or imipenem/cilastatin), or combination of tigecycline with some agents, may show promise with regard to successful management of MDR or PDR Acinetobacter baumannii pneumonia. Additionally, vancomycin plus rifampicin is an effective regimen against nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) responding poorly to vancomycin monotherapy. The clinical appropriateness of parenteral colistin against pneumonia caused by MDR A. baumannii has been established in a clinical trial. Facing the decline of clinical vancomycin efficacy after initial use, linezolid might be the drug of choice with regard to the treatment of MRSA-VAP. The role of tigecycline monotherapy for the management of nosocomial pneumonia caused by MRSA and extended-spectrum β-lactamase-producing Enterobacteriaceae needs to be cautiously evaluated.

KW - Acinetobacter baumannii

KW - colistin

KW - extended-spectrum β-lactamase

KW - methicillin-resistant Staphylococcus aureus

KW - multidrug-resistant

KW - nosocomial pneumonia

UR - http://www.scopus.com/inward/record.url?scp=80052619804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052619804&partnerID=8YFLogxK

U2 - 10.1517/14656566.2011.599320

DO - 10.1517/14656566.2011.599320

M3 - Article

VL - 12

SP - 2145

EP - 2148

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 14

ER -